Abstract
Recent randomized trials suggest that interleukin-6 inhibitors reduce mortality due to severe coronavirus disease 2019. Using a decision tree model, we found that tocilizumab is cost-effective with an estimated incremental cost-effectiveness ratio of $16 520 per quality-adjusted life year gained (95% credible interval, 10 760–51 530).
Funding Information
  • National Institutes of Health (R01DA046527, P30DA040500, 5T32AI052074–13)

This publication has 8 references indexed in Scilit: